Current Report Filing (8-k)
August 16 2019 - 09:49AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) August 15, 2019
PRESSURE
BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in its Charter)
MASSACHUSETTS
(State or Other Jurisdiction of Incorporation)
001-38185
|
|
04-2652826
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
14
Norfolk Avenue, South Easton, MA
|
|
02375
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(508) 230-1828
(Registrant’s Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
None
|
|
None
|
|
None
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Cautionary
Note Regarding Forward-Looking Statements
This
Current Report on Form 8-K includes information that may constitute forward-looking statements. These forward-looking statements
are based on the Company’s current beliefs, assumptions and expectations regarding future events, which in turn are based
on information currently available to the Company. By their nature, forward-looking statements address matters that are subject
to risks and uncertainties. Forward looking statements include, without limitation, statements relating to projected industry
growth rates, the Company’s current growth rates and the Company’s present and future cash flow position. A variety
of factors could cause actual events and results, as well as the Company’s expectations, to differ materially from those
expressed in or contemplated by the forward-looking statements. Risk factors affecting the Company are discussed in detail in
the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update
or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent
required by applicable securities laws.
Item
7.01 Regulation FD Disclosure.
On
August 15, 2019, Pressure BioSciences, Inc. (the “Company”) held an earnings phone call open to the public (the “Earnings
Call”). Mr. Richard T. Schumacher, Chief Executive Officer, discussed the financial and operating results of the Company
for the quarter ended June 30, 2019 as well as other items regarding the Company’s fiscal year 2019. Some of those items
included: (i) a key employee of the Company, Brad Young, voluntarily left
the
Company to pursue other opportunities
, (ii) the Company received two binding purchase orders for its UST-based BaroShear
K45 processing system for CBD nanoemulsification, and (iii) the Company executed an agreement with a large pharmaceutical
company whereby the Company will provide services related to its Barofold division.
The
information provided under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is “furnished”
and shall not be deemed “filed” with the Securities and Exchange Commission or incorporated by reference in any filing
under the Securities Exchange Act or 1934 or the Securities Act of 1933.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Dated:
August 16, 2019
|
PRESSURE
BIOSCIENCES, INC.
|
|
|
|
By:
|
/s/
Richard T. Schumacher
|
|
|
Richard
T. Schumacher,
|
|
|
President
and Chief Executive Officer
|
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Mar 2023 to Mar 2024